OBJECTIVE: The optimal management of stage II endometrial cancer remains uncertain. We examined the role of radical hysterectomy and adjuvant radiotherapy for stage II endometrial cancer. STUDY DESIGN: The Surveillance, Epidemiology, and End Results database was used to identify 1577 women with stage II endometrioid type endometrial adenocarcinoma who underwent surgical staging. RESULTS: The cohort included 1198 women who underwent simple hysterectomy (76%) and 379 who underwent radical hysterectomy (24%). Radical hysterectomy had no effect on survival (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.61-1.23). Patients who did not receive radiation were 48% (HR, 1.48; 95% CI, 1.14-1.93) more likely to die than those who underwent adjuvant radiotherapy. The survival benefit from radiation was most pronounced in women who underwent radical hysterectomy. CONCLUSION: Adjuvant radiation improves survival. Although the routine performance of radical hysterectomy does not appear to be justified, patients with high-risk stage II tumors appear to benefit from combination therapy with radical hysterectomy and radiotherapy.
OBJECTIVE: The optimal management of stage II endometrial cancer remains uncertain. We examined the role of radical hysterectomy and adjuvant radiotherapy for stage II endometrial cancer. STUDY DESIGN: The Surveillance, Epidemiology, and End Results database was used to identify 1577 women with stage II endometrioid type endometrial adenocarcinoma who underwent surgical staging. RESULTS: The cohort included 1198 women who underwent simple hysterectomy (76%) and 379 who underwent radical hysterectomy (24%). Radical hysterectomy had no effect on survival (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.61-1.23). Patients who did not receive radiation were 48% (HR, 1.48; 95% CI, 1.14-1.93) more likely to die than those who underwent adjuvant radiotherapy. The survival benefit from radiation was most pronounced in women who underwent radical hysterectomy. CONCLUSION: Adjuvant radiation improves survival. Although the routine performance of radical hysterectomy does not appear to be justified, patients with high-risk stage II tumors appear to benefit from combination therapy with radical hysterectomy and radiotherapy.
Authors: Barenya Mukerji; Caitlin Baptiste; Ling Chen; Ana I Tergas; June Y Hou; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Gynecol Oncol Date: 2018-01-05 Impact factor: 5.482
Authors: Pedro T Ramirez; Michael Frumovitz; Michael R Milam; Michael Deavers; Ricardo dos Reis; Revathy B Iyer; Priya Bhosale; Kathleen M Schmeler Journal: Int J Gynecol Cancer Date: 2010-11 Impact factor: 3.437
Authors: M Takano; H Ochi; Y Takei; M Miyamoto; Y Hasumi; Y Kaneta; K Nakamura; A Kurosaki; T Satoh; H Fujiwara; S Nagao; K Furuya; H Yokota; K Ito; T Minegishi; H Yoshikawa; K Fujiwara; M Suzuki Journal: Br J Cancer Date: 2013-09-03 Impact factor: 7.640
Authors: Gaurav Shukla; Sushil Beriwal; Thomas C Krivak; Joseph L Kelley; Paniti Sukumvanich; Robert P Edwards; Scott Richard; Alexander Olawaiye; Kristin K Zorn Journal: J Contemp Brachytherapy Date: 2011-07-06